Trial
NCT00470093
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI)
Condition
Multiple Myeloma and Plasma Cell Neoplasm
Intervention
recombinant interferon-α
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-16